{
    "name": "gadobutrol",
    "comment": "Rx",
    "other_names": [
        "Gadavist"
    ],
    "classes": [
        "Gadolinium-Containing Contrast Agents",
        "Contrast Media",
        "Nonionic/ High Osmolality"
    ],
    "source": "https://reference.medscape.com/drug/gadavist-gadobutrol-999634",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown",
            "All pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estimated infant exposure is 0.01%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant or from underlying maternal conditio"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis (NSF)",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination",
                        "Avoid use in these patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities",
                        "NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs",
                        "For patients at highest NSF risk, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration",
                        "Risk appears highest among patients with:",
                        "Chronic, severe kidney disease (GFR <30 mL/min/1.73 m²), or",
                        "Acute kidney injury",
                        "Monitoring",
                        "Screen for acute kidney injury and other conditions that may reduce renal function",
                        "Screen for risk of chronically reduced renal function (eg, aged >60 yr, hypertension, diabetes)",
                        "Estimate glomerular filtration rate (GFR) through laboratory testing"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "1.5"
        },
        {
            "name": "Nausea",
            "percent": "1.2"
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Feeling hot",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "Nephrogenic systemic fibrosis",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "anaphylactoid reactions",
            "percent": null
        }
    ]
}